本文系基于公开资料撰写,仅作为信息交流之用,不构成任何投资建议。辉瑞还是忘不掉“口服GLP-1”。在终止口服GLP-1核心管线danuglipron研发的八个月后,辉瑞再次出手引入“口服GLP-1”资产。12月9日,复星医药公告称,其自主研发的小分子胰高血糖素样肽-1 受体(GLP-1R)激动剂YP05002的全球独家权益将授予辉瑞。为了得到YP05002,辉瑞付出了1.5亿美元首付款,外加潜在的...
Source Link本文系基于公开资料撰写,仅作为信息交流之用,不构成任何投资建议。辉瑞还是忘不掉“口服GLP-1”。在终止口服GLP-1核心管线danuglipron研发的八个月后,辉瑞再次出手引入“口服GLP-1”资产。12月9日,复星医药公告称,其自主研发的小分子胰高血糖素样肽-1 受体(GLP-1R)激动剂YP05002的全球独家权益将授予辉瑞。为了得到YP05002,辉瑞付出了1.5亿美元首付款,外加潜在的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.